This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,169.59 contract is for the provision of 120 tablets of the prescription drug Xtandi (40 mg) with a performance period ending on November 8, 2024.
DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price delivery orders for a wide range of pharmaceutical products, including branded and generic drugs, biologics, and medical consumables. This delivery order is not associated with any specific set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple medical product categories.
Generated 2/6/25, 9:11 AM